Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Sweden
/
Pharmaceuticals & Biotech
Create a narrative
Oncopeptides Community
OM:ONCO Community
2
Narratives
written by author
1
Comments
on narratives written by author
5
Fair Values set
on narratives written by author
Create a narrative
Oncopeptides
Popular
Undervalued
Overvalued
Community Investing Ideas
Oncopeptides
DA
DailyInvestors
Community Contributor
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment In the ever-evolving landscape of oncology, Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is emerging as a company demonstrating significant promise.
View narrative
SEK 2.56
FV
25.4% undervalued
intrinsic discount
47.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
about 2 months ago
author updated this narrative
Oncopeptides
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Agreements In Europe And Japan Will Unlock Global Markets
Key Takeaways Strategic agreements in Europe and potential licensing in Japan will unlock major markets, enhancing future earnings and revenue growth. Cost management alongside sales expansion in core European markets aims to achieve cash flow positivity, positively impacting net margins by 2026.
View narrative
SEK 2.50
FV
23.6% undervalued
intrinsic discount
120.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Your Valuation for
ONCO
ONCO
Oncopeptides
Your Fair Value
SEK
Current Price
SEK 1.91
9.8% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-2b
333m
2015
2018
2021
2024
2025
2027
2030
Revenue SEK 333.5m
Earnings SEK 65.3m
Advanced
Set Fair Value